Scarica l'app Stockscreener
53.08
3.32%
-1.82
Precedente Chiudi:
$54.90
Aprire:
$54.62
Volume 24 ore:
565.25K
Relative Volume:
1.03
Capitalizzazione di mercato:
$1.47B
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-8.7303
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
+6.74%
1M Prestazione:
+10.30%
6M Prestazione:
+156.18%
1 anno Prestazione:
+175.17%
Intervallo 1D:
$52.55
$57.65
Intervallo di 1 settimana:
$46.85
$57.65
Portata 52W:
$14.46
$57.65
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
53.08 | 1.52B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio (NASDAQ:ANAB) Insider Sells $540,000.00 in Stock - MarketBeat
Risk Off: Can AnaptysBio Inc grow without external fundingJuly 2025 Trade Ideas & Safe Swing Trade Setups - baoquankhu1.vn
Page not foundAirwhon - MarketBeat
AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 - Yahoo Finance
ANAB: Separation in Q2 will unlock value from Jemperli royalties and advance a promising clinical pipeline - TradingView
AnaptysBio stock hits 52-week high at $52.56 By Investing.com - Investing.com South Africa
Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge? - Yahoo Finance
(ANAB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Market Trends: Is AnaptysBio Inc a momentum stockDollar Strength & Real-Time Stock Price Movement Reports - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighShould You Buy? - MarketBeat
AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts - MarketBeat
AnaptysBio stock hits 52-week high at $52.56 - Investing.com
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte, Novartis - Barchart.com
Will AnaptysBio Inc. outperform its industry peers2025 Key Lessons & Growth Focused Entry Point Reports - mfd.ru
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Momentum Shift: Is AnaptysBio Inc in a consolidation phase2025 Dividend Review & Free Long-Term Investment Growth Plans - baoquankhu1.vn
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Anaptys Announces Participation at Upcoming Investor Conferences - Sahm
AnaptysBio to participate in investor conferences. CEO to attend for discussions on immunology therapeutics. - Longbridge
Sentiment Review: Is GTIM in a long term uptrendJuly 2025 Macro Moves & Safe Entry Trade Reports - baoquankhu1.vn
Biotech Leader Eyes Spinoff Amid Massive Sales Surge - Investor's Business Daily
Federated Hermes Inc. Increases Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
Responsive Playbooks and the ANAB Inflection - Stock Traders Daily
Inflation Data: Will BTCT benefit from rising consumer demandWeekly Stock Analysis & Verified Swing Trading Watchlist - baoquankhu1.vn
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral - MSN
Can AnaptysBio Inc. reach all time highs this yearQuarterly Trade Summary & Daily Stock Trend Reports - mfd.ru
Bear Alert: Is AnaptysBio Inc undervalued by DCF analysisDollar Strength & Daily Stock Trend Reports - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup - ChartMill
Assessing AnaptysBio (ANAB) Valuation As Technical Strength Meets Improving Profitability Prospects - Sahm
CD122’s double whammy makes for intriguing target - BioWorld MedTech
Understanding the Setup: (ANAB) and Scalable Risk - Stock Traders Daily
Treasury Yields: Will AnaptysBio Inc benefit from geopolitical trendsJuly 2025 Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Barclays Raises Price Target for AnaptysBio (ANAB) to $78.00 | A - GuruFocus
Did Big EPS, Revenue Jump and JPM Spotlight Just Shift AnaptysBio's (ANAB) Investment Narrative? - simplywall.st
ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment - Chartmill
AnaptysBio Shares Face Pressure Amid Insider Sale and Strategic Uncertainty - AD HOC NEWS
Market Leaders: Is AnaptysBio Inc stock a good dividend stock2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Anaptysbio director Marquet sells $530k in shares By Investing.com - Investing.com Nigeria
AnaptysBio (NASDAQ:ANAB) Director Magda Marquet Sells 11,000 Shares - MarketBeat
Anaptysbio director Marquet sells $530k in shares - Investing.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Breakout Zone: Can AnaptysBio Inc generate free cash flowWeekly Stock Analysis & Real-Time Volume Trigger Notifications - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Stock Price Down 7.3%Time to Sell? - MarketBeat
Rally Mode: Is AnaptysBio Inc a momentum stock2025 Winners & Losers & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
AnaptysBio Teases 2026 Split, JEMPERLI Royalty Upside and Key Clinical Catalysts at JPM Conf - MarketBeat
ANAB: Separation into two focused entities targets value creation, with major clinical and royalty catalysts ahead - TradingView — Track All Markets
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally - AOL.com
AnaptysBio (NASDAQ:ANAB) Stock Price Up 7.2%Time to Buy? - MarketBeat
AnaptysBio stock: UBS reiterates Buy rating amid ongoing GSK litigation By Investing.com - Investing.com Canada
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock By Investing.com - Investing.com Nigeria
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anaptysbio Inc Azioni (ANAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Feb 11 '26 |
Sale |
54.00 |
10,000 |
540,000 |
12,835 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):